IMGN ข่าวฟอเร็กซ์
AbbVie To Acquire ImmunoGen For $31.26/shre In All-cash Deal Of About $10.1 Bln
AbbVie Inc. (ABBV) and ImmunoGen, Inc. (IMGN) announced Thursday AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC).
RTTNews
|
333 วันที่ผ่านมา
ImmunoGen Inks Multi-Target License Deal With ImmunoBiochem For Next-Gen Antibody-Drug Conjugates
ImmunoGen, Inc. (IMGN) announced Monday a multi-target license and option agreement to research novel, first-in-class ADCs with privately-held biopharmaceutical company ImmunoBiochem Corp.
RTTNews
|
462 วันที่ผ่านมา
ImmunoGen, Oxford BioTherapeutics To Collaborate To Develop Novel Antibody-Drug Conjugates
ImmunoGen Inc. (IMGN), a developer of antibody-drug conjugates (ADCs) for the treatment of cancer, announced Monday a multi-year collaboration to research novel, first-in-class ADCs with clinical stage oncology company Oxford BioTherapeutics (OBT), utilizing ImmunoGen's proprietary linker-payload technology directed to novel targets identified via OBT's proprietary OGAP discovery platform.
RTTNews
|
868 วันที่ผ่านมา
